Premium
O1‐03‐01: APP accelerates death and alters physical connectivity of mouse olfactory sensory neurons
Author(s) -
Albers Mark
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.239
Subject(s) - olfactory bulb , genetically modified mouse , biology , neuroscience , neurodegeneration , sensory system , olfactory system , transgene , olfactory ensheathing glia , population , phenotype , microbiology and biotechnology , central nervous system , pathology , genetics , gene , disease , medicine , environmental health
demonstrate the protective effect of interventions, subjects are randomized into one of the following four groups: omega 3 alone, multidomain intervention alone, omega 3 plus multidomain intervention or placebo (n 1⁄4 420 each). The principal outcome measure is a change in cognitive function at 3 years, as determined by the Grober and Buschke Test. Results: A total of 2,388 subjects were screened to date for participation, of whom 1,556 fulfilled the eligibility criteria and were entered into the study. Inclusions will be closed by February 28th. Conclusions: The MAPT Study is the first preventive trial involving multidomain interventions and omega 3. It will enable us to assess the usefulness of various baseline characteristics as predictors of cognitive decline in frail older people.